SpringWorks Therapeutics Licenses RPT04402 for Innovative Cancer Therapy Development
- SpringWorks Therapeutics secured an exclusive license for RPT04402, an innovative anti-cancer drug from Rappta Therapeutics.
- The collaboration includes a $13 million upfront payment and potential financial incentives linked to clinical milestones.
- SpringWorks plans to file an IND application by the end of 2025 to advance RPT04402's development and commercialization.
SpringWorks Therapeutics Teams Up with Rappta for Groundbreaking Cancer Therapy
SpringWorks Therapeutics has secured an exclusive global license for RPT04402, an innovative anti-cancer drug developed by Rappta Therapeutics. This pioneering treatment is designed to selectively target Protein Phosphatase 2A (PP2A) complexes, which play a critical role in tumor suppression but have historically been difficult to target. The collaboration entails a $13 million upfront payment from SpringWorks, as well as potential financial incentives tied to clinical, regulatory, and commercial milestones, alongside tiered royalties based on net sales. The agreement marks a significant commitment from SpringWorks to advance a therapy that addresses a pressing need in cancer treatment.
RPT04402 has demonstrated promising results in pre-clinical models, particularly for patients with PP2A mutant uterine cancer, where it has achieved rapid and durable tumor regressions as a monotherapy. This effectiveness underscores the potential of the drug to fill a critical gap in the current oncology landscape. With plans to file an Investigational New Drug (IND) application by the end of 2025, SpringWorks is poised to spearhead the global development and commercialization of RPT04402, aiming to bring this transformative therapy to patients who are currently underserved by existing treatment options.
Rappta’s team, led by CEO Sunjeet Sawhney and Chief Scientific Officer Goutham Narla, emphasizes the unique opportunity this collaboration presents. Narla highlights their proprietary structural data that enables the creation of a first-in-class molecular glue, which reactivates PP2A to combat various cancers. The partnership is not just about RPT04402; it symbolizes a broader commitment to developing new classes of anti-cancer drugs aimed at addressing the unmet clinical needs of patients suffering from cancers associated with PP2A mutations.
In addition to the promising potential of RPT04402, this partnership reflects a growing trend in the oncology sector, as companies increasingly focus on precision medicine and targeted therapies. The collaboration between SpringWorks and Rappta showcases a proactive approach to tackling complex cancer mechanisms, which could ultimately lead to more effective treatments and improved patient outcomes.
As SpringWorks prepares to move forward with RPT04402, the collaboration serves as a reminder of the significant advancements being made in cancer research. This joint effort not only aims to enhance treatment options for patients with specific genetic profiles but also underscores the importance of innovative partnerships in the fight against cancer.